Short Communication: HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences

AIDS Res Hum Retroviruses. 2021 Jan;37(1):54-56. doi: 10.1089/AID.2020.0022. Epub 2020 Aug 10.

Abstract

HIV-1 integrase (IN) is a primary target for combination antiretroviral therapy. Only a limited number of studies report on the emergence of resistance-associated mutations (RAMs) in Cameroon. We observed that 1.4% of sequence from treatment-naive patients had IN strand transfer inhibitor (INSTI) RAMs. These mutations confer resistance to raltegravir and elvitegravir. We also observed that 10.1% of the sequences have INSTI accessory RAMs. HIV-1 CRF02_AG was the predominant subtype (44.7%) in this study analyses. The occurrence of INSTI RAMs among the sequences at baseline needs to be monitored carefully.

Keywords: CRF02_AG; Cameroon; HIV-1; diversity; integrase; resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cameroon / epidemiology
  • Drug Resistance, Viral / genetics
  • Genotype
  • HIV Infections* / drug therapy
  • HIV Integrase Inhibitors* / pharmacology
  • HIV Integrase Inhibitors* / therapeutic use
  • HIV Integrase* / genetics
  • HIV-1* / genetics
  • Humans
  • Mutation
  • Raltegravir Potassium / therapeutic use

Substances

  • HIV Integrase Inhibitors
  • Raltegravir Potassium
  • HIV Integrase